Abeona stock rises on new data for rare skin disorder drug
Gorodenkov Abouna Remedies (Nasdaq: ABEO) reported additional data from a phase 3 trial of EB-101 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB) at the International Societies for Investigative Dermatology (ISID)…
